Valproic acid potentiates both typical and atypical antipsychotic-induced prefrontal cortical dopamine release

Brain Research

Volumn 1052, Issue 1, 2005, Pages 56-62

  Ichikawa, Junji ^a   Chung, Young Chul ^a   Dai, Jin ^a   Meltzer, Herbert Y ^a  

^a Psychiatric Hospital at Vanderbilt   (United States)

Author keywords

5 HT1A receptor agonism; Atypical antipsychotic drug; Cortical and accumbal dopamine release; Mood stabilizer; Valproic acid

Indexed keywords

CLOZAPINE; HALOPERIDOL; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; RISPERIDONE; VALPROIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COGNITION; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG EFFECT; DRUG POTENTIATION; MALE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; RECEPTOR BINDING;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN CHEMISTRY; CEREBRAL CORTEX; DIALYSIS; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; MALE; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; VALPROIC ACID;

EID: 23644443835     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2005.06.009     Document Type: Article

References (45)

1. A. Abi-Dargham Do we still believe in the dopamine hypothesis? New data bring new evidence Int. J. Neuropsychopharmacol. 7 Suppl. 1 2004 S1 S5
2. 1 receptors and the pathology of schizophrenia Neuroscientist 9 2003 404 416
3. 1 receptors and working memory in schizophrenia J. Neurosci. 22 2002 3708 3719
4. A. Aleman, and E.H. de Haan Antipsychotics and working memory in schizophrenia Science 289 2000 56 58
5. J.L. Andersson, G.G. Nomikos, M. Marcus, P. Hertel, J.M. Mathe, and T.H. Svensson Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectively in the mesolimbic dopaminergic system Naunyn-Schmiedeberg's Arch. Pharmacol. 352 1995 374 385
6. L. Arborelius, G.G. Nomikos, U. Hacksell, and T.H. Svensson (R)-8-OH-DPAT preferentially increases dopamine release in rat medial prefrontal cortex Acta Psychiatr. Scand. 148 1993 465 466
7. 2 receptor mechanisms contribute to age-related cognitive decline: the effects of quinpirole on memory and motor performance in monkeys J. Neurosci. 15 1995 3429 3439
8. 2A/2C receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens Neuropsychopharmacology 27 2002 430 441
9. G. Chen, M.I. Masana, and H.K. Manji Lithium regulates PKC-mediated intracellular cross-talk and gene expression in the CNS in vivo Bipolar Disord. 2 2000 217 236
10. 1A receptor agonism Brain Res. 1023 2004 54 63
11. K.L. Davis, R.S. Kahn, K. Grant, and M. Davidson Dopamine in schizophrenia: a review and reconceptualization Am. J. Psychiatry 148 1991 1474 1486
12. 3H]SCH23390 binding in the cerebral cortex of postmortem brains of chronic schizophrenics J. Neural Transm. 108 2001 1475 1484
13. M.F. Egan, T.E. Goldberg, B.S. Kolachana, J.H. Callicott, C.M. Mazzanti, R.E. Straub, D. Goldman, and D.R. Weinberger Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia Proc. Natl. Acad. Sci. 98 2001 6917 6922
14. 1 receptor in schizophrenia: insights for cognitive dysfunction Psychopharmacology 174 2004 3 16
15. M.F. Green, S.R. Marder, S.M. Glynn, S.R. McGurk, W.C. Wirshing, D.A. Wirshing, R.P. Liberman, and J. Mintz The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone Biol. Psychiatry 51 2002 972 978
16. 1 receptor radioligands: implications for imaging studies in schizophrenia Neuropsychopharmacology 28 2003 1703 1711
17. P.D. Harvey, and R.S. Keefe Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment Am. J. Psychiatry 158 2001 176 184
18. 2 adrenoceptor blockade Science 286 1999 105 107
19. 1A receptor activation Eur. J. Pharmacol. 380 1999 R1 R3
20. 1A receptor agonist, potentiated S(-) sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum J. Pharmacol. Exp. Ther. 291 1999 1227 1232
21. 1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release J. Neurochem. 76 2001 1521 1531
22. 1A receptor agonism Brain Res. 956 2002 349 357
23. 1A receptor agonism, Brain Res. (in press).
24. 1 dopamine receptor binding in neuroleptic-naive patients with schizophrenia Am. J. Psychiatry 159 2002 761 767
25. M.B. Knable, T.M. Hyde, A.M. Murray, M.M. Herman, and J.E. Kleinman A postmortem study of frontal cortical dopamine D1 receptors in schizophrenics, psychiatric controls, and normal controls Biol. Psychiatry 40 1996 1191 1199
26. M.B. Knable, E.F. Torrey, M.J. Webster, and J.J. Bartko Multivariate analysis of prefrontal cortical data from the Stanley Foundation Neuropathology Consortium Brain Res. Bull. 55 2001 651 659
27. T. Kuroki, H.Y. Meltzer, and J. Ichikawa Effect of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens J. Pharmacol. Exp. Ther. 288 1999 774 781
28. 2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner Brain Res. 947 2002 157 165
29. W. Löscher Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action Prog. Neurobiol. 58 1999 31 59
30. S.R. McGurk, K.T. Mueser, D. Walling, P.D. Harvey, and H.Y. Meltzer Cognitive functioning predicts outpatient service utilization in schizophrenia Ment. Health Serv. Res. 6 2004 185 188
31. H.Y. Meltzer Cognitive factors in schizophrenia: causes, impact, and treatment CNS Spectr. 9 Suppl. 11 2004 15 24
32. H.Y. Meltzer, and S.R. McGurk The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia Schizophr. Bull. 25 1999 233 255
33. B. Moghaddam, and B.S. Bunney Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study J. Neurochem. 54 1990 1755 1760
34. B.L. Murphy, A.F. Arnsten, P.S. Goldman-Rakic, and R.H. Roth Increased dopamine turnover in the prefrontal cortex impairs spatial working memory performance in rats and monkeys Proc. Natl. Acad. Sci. 93 1996 1325 1329
35. 1 receptors in schizophrenia revealed by PET Nature 385 1997 634 636
36. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates Fourth ed. 1998 Academic Press New York
37. E.A. Pehek, and B.K. Yamamoto Differential effects of locally administered clozapine and haloperidol on dopamine efflux in the rat prefrontal cortex and caudate-putamen J. Neurochem. 63 1994 2118 2124
38. 1A receptor activation Eur. J. Pharmacol. 338 1997 R3 R5
39. 1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex Biol. Psychiatry 48 2000 229 237
40. 1A receptor activation increases in vivo dopamine release in rat prefrontal cortex Br. J. Pharmacol. 129 2000 1028 1034
41. G. Tanda, E. Caroni, R. Frauand, and G. Di Chiara Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacology 115 1994 285 288
42. M. Volonté, E. Monferini, M. Cerutti, F. Fodritto, and F. Borsini BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex J. Neurochem. 69 1997 182 190
43. 1 receptors in prefrontal cortex Nature 376 1995 572 575
44. N.D. Woodward, S.E. Purdon, H.Y. Meltzer, and D.H. Zald A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia Int. J. Neuropsychopharmacol. 8 2005 457 472
45. 1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance J. Neurosci. 17 1997 8528 8535